Loo E, Khalili P, Beuhler K, et al. BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2018;26(10):709-713.
Davies H, Bigneli G, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
Croce L, Coperchini F, Magri F, et al. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget. 2019;10(61):6623-6640.
Korphaisarn K, Kopetz S. BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer J. 2016;22(3):175-178.
Ducreux M, Chamseddine A, Laurent-Puig P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019;11:1758835919856494.
Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364:2305-2315.
Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
Danu A, Cotteret S, Lacroix L, et al. BRAF V600E targetable mutation in relapsed/refractory multiple myeloma (R/R MM) patients: A high incidence in R/R MM detected using cell sorting screening. Blood. 2016;128(22):5638.
Moulana FI, Priyani AAH, de Silva MVC, et al. BRAF-oncogene-induced senescence and the role of thyroid-stimulating hormone signaling in the progression of papillary thyroid carcinoma. Horm Canc. 2018;9:1-11.
Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466-471.
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
